<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061251</url>
  </required_header>
  <id_info>
    <org_study_id>BAY 2402234</org_study_id>
    <nct_id>NCT05061251</nct_id>
  </id_info>
  <brief_title>Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma</brief_title>
  <official_title>An Open-Label Surgical Window of Opportunity Study Evaluating Pharmacodynamic Response of Orally Administered BAY 2402234 in Subjects With Recurrent Glioma, IDH Mutant, Grade 3 or 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to look at how BAY 2402234 responds in body in patients with recurrent&#xD;
      glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To characterize the biological activity of BAY 2402234 in recurrent glioma, IDH-mutant, Grade&#xD;
      3/4 using liquid chromatography-mass spectrometry (LC-MS). The tissue orotate:carbamoyl&#xD;
      aspartate ratio will serve as the primary pharmacodynamic biomarker and will be characterized&#xD;
      via LC-MS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biological activity of BAY 2402234</measure>
    <time_frame>3 days up tp day of surgery</time_frame>
    <description>The primary endpoint is to characterize the biological activity of BAY 2402234 using liquid chromatography-mass spectrometry (LC-MS). The tissue orotate:carbamoyl aspartate ratio will serve as the primary pharmacodynamic biomarker and will be characterized via LC-MS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Monitoring</measure>
    <time_frame>28 days after the final administered dose of BAY 2402234</time_frame>
    <description>To monitor adverse events during treatment with BAY 2402234 and document them in accordance with the Common Technology Criteria for Adverse Events (CTCAE) Version 5.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Glioma</condition>
  <condition>IDH Mutation</condition>
  <arm_group>
    <arm_group_label>BAY 2402234</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 dose (5mg) orally, per day of BAY 2402234 for the 2 days prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery, for a total of 3 administered doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 2402234</intervention_name>
    <description>Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.</description>
    <arm_group_label>BAY 2402234</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years of age&#xD;
&#xD;
          -  Histologically and/or genomically documented recurrent or progressive astrocytoma,&#xD;
             IDH-mutant, grade 3 or 4 (diagnosis established by the presence of an IDH1 or IDH2&#xD;
             mutation along with grade 3 or 4 radiographic findings)&#xD;
&#xD;
          -  Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to&#xD;
             dosing, or surgical confirmation of recurrent disease&#xD;
&#xD;
          -  Performance status measured via Karnofsky Performance Score of ≥ 60&#xD;
&#xD;
          -  Confirmed measurable disease per response assessment in neuro-oncology criteria (RANO)&#xD;
&#xD;
          -  Participants should have at least one 1.5cm x 1.5cm region of enhancing and&#xD;
             non-enhancing tumor within the surgically accessible region&#xD;
&#xD;
          -  Ability of neurosurgeon to resect tumor&#xD;
&#xD;
          -  Laboratory values at the Screening Visit:&#xD;
&#xD;
               -  ANC count ≥1,500/mm3;&#xD;
&#xD;
               -  Platelets ≥150,000/mm3;&#xD;
&#xD;
               -  Hemoglobin &gt; 9g/dL&#xD;
&#xD;
               -  Total bilirubin ≤1.5 × the upper limit of normal (ULN) (subjects with Gilbert's&#xD;
                  Syndrome are allowed if direct bilirubin is within normal limits)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST [SGOT]) ≤3× the ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT [SGPT]) ≤3 × the ULN&#xD;
&#xD;
               -  Serum creatinine ≤1.5 mg/dL or a calculated creatinine clearance ≤60 mL/min&#xD;
&#xD;
               -  Negative serum B-hCG test in women of childbearing potential (defined as women&#xD;
                  ≤50 years of age, or &gt;50 years of age with a history of amenorrhea for ≤12 months&#xD;
                  prior to study entry)&#xD;
&#xD;
          -  All men, as well as women of child-bearing potential must agree to use dual&#xD;
             contraceptive methods (hormonal or barrier method of birth control; abstinence) while&#xD;
             on the study drug and for 3 months afterward. Men must also refrain from sperm&#xD;
             donation for 4 months after treatment with BAY 2402234. Should a woman become pregnant&#xD;
             or suspect she is pregnant while participating in this study, she should inform her&#xD;
             treating physician immediately.&#xD;
&#xD;
          -  A female of child-bearing potential is any woman (regardless of sexual orientation,&#xD;
             marital status, having undergone a tubal ligation, or remaining celibate by choice)&#xD;
             who meets the following criteria:&#xD;
&#xD;
               -  Has not undergone a hysterectomy or bilateral oophorectomy; or&#xD;
&#xD;
               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,&#xD;
                  has had menses at any time in the preceding 12 consecutive months).&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under age 18 (due to fundamental difference between pediatric and adult&#xD;
             gliomas)&#xD;
&#xD;
          -  Treatment with an IDH inhibitor within 90 days of enrollment&#xD;
&#xD;
          -  Treatment with temozolomide less than 23 days from study initiation, treatment with&#xD;
             CCNU or BCNU less than 42 days from study initiation, or treatment with any&#xD;
             cancer-directed systemic therapy less than 4 weeks or 5 half-lives from study&#xD;
             initiation, whichever is shorter&#xD;
&#xD;
          -  Any immunomodulatory drug or molecularly targeted, monoclonal antibody, within 14 days&#xD;
             prior to initiation of study drug&#xD;
&#xD;
          -  Use of any investigational agents within 28 days of baseline or 5 half-lives from&#xD;
             study initiation, whichever is shorter&#xD;
&#xD;
          -  Increasing corticosteroid requirement or a dose of &gt;24mg per day of dexamethasone or&#xD;
             an equivalent dose of other corticosteroids for longer than 48 hours within 7 days&#xD;
             prior to study initiation&#xD;
&#xD;
          -  Radiotherapy within 12 weeks prior to registration unless surgical confirmation of&#xD;
             recurrent disease&#xD;
&#xD;
          -  Presence of an acute or chronic toxicity of prior chemotherapy, with the exception of&#xD;
             alopecia or lymphopenia, that has not resolved to ≤ Grade 1, as determined by National&#xD;
             Cancer Institute CTCAE v5.0&#xD;
&#xD;
          -  Major surgery within 28 days prior to initiation of study drug&#xD;
&#xD;
          -  Active or clinically unstable bacterial, viral, or fungal infection requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Known human immunodeficiency virus or acquired immunodeficiency syndrome-related&#xD;
             illness&#xD;
&#xD;
          -  Any of the following within 6 months prior to initiation of study drug: uncontrolled&#xD;
             congestive heart failure (New York Heart Association Classification 3 or 4), angina,&#xD;
             myocardial infarction, cerebrovascular accident, coronary or peripheral artery bypass&#xD;
             graft surgery, transient ischemic attack&#xD;
&#xD;
          -  Pulmonary embolism within 1 month prior to initiation of study drug&#xD;
&#xD;
          -  Unstable cardiac dysrhythmias or persistent prolongation of the QTc interval to &gt;450&#xD;
             msec for males or &gt;470 msec for females&#xD;
&#xD;
          -  Any contraindication to contrast-enhanced MRI examination&#xD;
&#xD;
          -  Evidence of clinically significant intracranial hemorrhage&#xD;
&#xD;
          -  Previous history of an additional emergency, except for non-squamous-cell carcinoma of&#xD;
             skin or carcinoma-in-situ of the uterine cervix, unless the tumor was treated with&#xD;
             curative intent more than 2 years prior to study entry&#xD;
&#xD;
          -  Requires anti-seizure medications that are known to be strong inducers of CYP3A4/5&#xD;
             enzymes (carbamazepine, phenobarbital, phenytoin). Strong inhibitors and/or strong&#xD;
             inducers of CYP3A4 should not be administered within 14 days or 5 half-lives&#xD;
             (whichever is shorter) of the start of BAY 2402234 treatment, or during BAY 2402234&#xD;
             treatment, unless there is an emergent or life-threatening medical condition&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Any severe, acute, or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration, may interfere with the informed consent process and/or with&#xD;
             compliance with the requirements of the study, or may interfere with the&#xD;
             interpretation of study results and, in the Investigator's opinion, would make the&#xD;
             subject inappropriate for entry into this study&#xD;
&#xD;
          -  Difficulty swallowing or malabsorption syndrome; refractory nausea &amp; vomiting, chronic&#xD;
             gastrointestinal disease or previous significant bowel resection with clinically&#xD;
             significant sequelae that would preclude adequate absorption of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalil g Abdullah, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern/ Simmons CC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathrina Siaron, BSN CCRN</last_name>
    <phone>214-645-4673</phone>
    <email>Kathrina.Siaron@UTSouthwestern.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Kalil Abdullah</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

